chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pain in her arm; Could not sleep; Dehydrated; With the vaccine her symptoms were worse; Could not get warm; Body aches; Vomiting; Chills; Extreme nausea; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Pain in her arm), INSOMNIA (Could not sleep), DEHYDRATION (Dehydrated), CONDITION AGGRAVATED (With the vaccine her symptoms were worse) and FEELING COLD (Could not get warm) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037k20a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 (Had Covid-19 three weeks prior to vaccination) from 27-Dec-2020 to 10-Jan-2021, Benign meningioma in May 2001 and Exercise induced asthma (Exercise/allergy induced asthma since childhood.). Concurrent medical conditions included Hashimoto's disease since 2003. Concomitant products included CETIRIZINE HYDROCHLORIDE (ALLER TEC) for Allergy, MAGNESIUM GLYCINATE for Brain damage, LEVOTHYROXINE SODIUM (SYNTHROID) for Hashimoto's disease, FISH OIL, OENOTHERA BIENNIS OIL, TOCOPHERYL ACETATE (OMEGA 3 & 6) and ASCORBIC ACID, ZINC CITRATE (ZINC + VITAMIN C) for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced PAIN IN EXTREMITY (Pain in her arm), INSOMNIA (Could not sleep), DEHYDRATION (Dehydrated), CONDITION AGGRAVATED (With the vaccine her symptoms were worse), FEELING COLD (Could not get warm), MYALGIA (Body aches), VOMITING (Vomiting), CHILLS (Chills) and NAUSEA (Extreme nausea). At the time of the report, PAIN IN EXTREMITY (Pain in her arm), INSOMNIA (Could not sleep), DEHYDRATION (Dehydrated), CONDITION AGGRAVATED (With the vaccine her symptoms were worse), FEELING COLD (Could not get warm), MYALGIA (Body aches), VOMITING (Vomiting), CHILLS (Chills) and NAUSEA (Extreme nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood thyroid stimulating hormone: normal (normal) within normal limits.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient reported that she got Covid-19 around the holidays.   The patient  wanted to know about dosing of covid-19 vaccination, after having Covid-19, and if there was a wait time. She also wanted to know about common side effects after Covid-19 vaccination and that she would not get her second dose.  On 17-Jan-2021, the patient went to the emergency room (ER).  Treatment included IV Fluids, two pushes of Zofran (ondansetron) and Toradol (ketorolac).She was prescribed sublingual Zofran.   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Email address of the reporter. On 17-Apr-2021: No specific follow-up information recorded.
2.5 - 3" diameter pink area over injection site, mildly tender to touch. 02/02/2018 14:19. Telephone Encounter note. Patient calls to report a "mild reaction" to the PPSV23 vaccine which was given L lower deltoid on 1/30/18. Patient states noting a 2.5-3 inch diameter pink area over the injection site, mildly tender to touch. Denies any difficulty breathing, angioedema or other s/s anaphylaxis. States "It's very minor, just doing what I was told and reporting any reaction." Advised to apply cold compress to alleviate discomfort and that it should resolve within a few days. Agrees to call triage with any worsening sx and to report to local ER or call 911 with my with any sx of anaphylaxis. Sx reviewed, patient verbalizes understanding. Will call writer back on Monday if not resolved. Verbally agrees to have reaction reported to VAERS.
Approximately 24 hours after receiving her flu shot, patient had a seizure.  She was seen in the ER immediately and looking well.  Discharged home.   That night began having intractable seizures of unclear etiology.   Admitted to the ICU within a day and has been there since then.  Currently intubated and still no cause found for the new onset seizures.  I do not know if her flu shot causes this, but no other cause has been found and this was the only thing that was different in the 24 hours preceding her illness.  I am obligated to report this for the POSSIBILITY that it could be connected.
Patient received first vaccine on 1/23/2021 and came back late for second vaccine.
Pt received vaccine on 2/25/21. Presented to emergency department on 2/28/21 with c/o hives (generalized) and arm burning sensation starting 2/27/21. Pt received famotidine, methylprednisolone, and diphenhydramine in the ED; was discharged to home.
This case was reported by a physician via sales rep and described the occurrence of injection site blisters in a patient who received BEXSERO for prophylaxis. On an unknown date, the patient received BEXSERO at an unknown dose. On an unknown date, unknown after receiving BEXSERO, the patient experienced injection site blisters. On an unknown date, the outcome of the injection site blisters was unknown. It was unknown if the reporter considered the injection site blisters to be related to BEXSERO. Additional details were provided as follows: The reporting physician had reported this case previously to VAERS. The age at vaccination was not reported. The physician stated that he had the patient, who had blistering at the injection site, after administration of BEXSERO. This case was linked with US2018GSK123551, reported by the same reporter.
began feeling dizzy about 2 hours after receiving the vaccine.  Then became very tired and took a nap for several hours.  Dizziness subsided.
24 hours after, severe pain in arm and needed help to perform normal tasks. Just 12/12, visited hospital for COPD. Soreness to touch and bruising. Was told by NP to stop taking Eliquis. Bruising subsided eventually and light pain.
Pt. with IDDM, with typically significant issues with hyperglycemia, immediately (approximately 2 hrs) after vaccination with "sick" feeling and now approximately 3 week H/O hypoglycemic episodes. After received 3rd HPV.
The patient was observed for 15 minutes in the observation area without incident.  She arose and walked to the exit and then apparently fainted on the sidewalk outside the vaccination clinic.  She was attended to by medical staff on site and because she was responding slower than expected and complained of pain on the right side of her head and weakness of her left arm and leg an ambulance was called via 911.  Care was assumed by paramedics who placed her in the ambulance where she was warmed and examined further.  She eventually denied any continuing pain or weakness (per ambulance crewman) and she was released to the care of her boyfriend / fiance.
Full torso, arms and neck skin rash started 1 week after injection, and lasted for one week.
Low grade fever (100-107 F) multiform rash on face only.  No (grand or trunk) or est or surface.
Narrative:  HOSPITALIZED WITH COVID-19 PNEUMONIA AFTER FULL VACCINATION. Patient is an 81-year-old female Covid vaccinated, with PMH of COPD on HOT at 3 LPM NC, chronic kidney disease stage 3, chronic neuropathy, GERD admitted after presenting to the ED with feeling weak ,not eating well and shortness of breath after exposed to her son sick from Covid.At ED Covid detected with increase need of O2 to 4 LPM NC and with abnormal LFTs unable to start IV remdesivir,CXRAY: + GGO/Covid pneumonia. Patient's condition improved and she was discharged to home.
developed bilateral swelling and cough/subjective shortness of breath.  Found to have bilateral DVT with likely several PEs (not confirmed).  Patient started on SQ Lovenox.
Strong tingling, numbness and pain from injection site to tips of fingers for about 2-3 weeks after vaccine.  Pain has subsided.  Tingling and numbness is not as strong however still persists from injection site to tip of fingers.
2nd dose at the end of March2020; severe cut on leg; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose at the end of March2020) and WOUND (severe cut on leg) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029420A) for COVID-19 vaccination.     The patient's past medical history included Chemotherapy. Concurrent medical conditions included Cancer (Chronic cancer).    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced WOUND (severe cut on leg). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose at the end of March2020). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose at the end of March2020) and WOUND (severe cut on leg) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient received tetanus shot because she had severe cut. Due to that 2nd dose is scheduled on different date then usual scheduled date.  In the follow-up form patient states that she did receive 2nd dose nearly 2 months after the first one &  few days after she had chemotherapy.  Concomitant medication information was not provided.  Treatment information were not provided.   Most recent FOLLOW-UP information incorporated above includes: On 21-Jul-2021: Received on 20 Jul 2021, patient updated about second dose
Felt weak, went to sleep unusually early, slept for over 4 hours, awoke with pain at vaccination site, headache.  Took pain relief (Tylenol) and returned to sleep for the rest of the night.  Had flu-like symptoms for several days after, and the pain at the vaccination site persisted even after other symptoms subsided. Noticeable pain and weakness in left shoulder, particularly upon waking.  Five months later, I continue to have pain around the shot-site, as well as persistent and increasing pain and weakness in the shoulder socket.
Erythema area on left upper arm at injection site 60 mm wide by 50 mm high.  Warm to touch.  No induration noted.
Information has been received from the Aunt of an 18 year old female consumer who on an unspecified date was vaccinated, IM with a dose of GARDASIL (dosage not provided) for the prevention of cervical cancer. It was reported that, on an unspecified date, the patient "developed an enlarged lymph node on the left side, supra clavicular, which was diagnosed as infected lymph node at first. She was given an antibiotic. But later went to the ER and found out she had cancer stage 3 Hodgkins lymphoma type D. It was a 3cm lymph node from the right axilla", requiring chemo, portacath and bone marrow biopsy. It was reported the patient also had a chest x-ray, cat scan w/ contrast, a PETscan, blood work and had an ovary removed to harvest an egg. At the time of the report, the patient had not recovered. Upon internal review, cancer stage 3 Hodgkins lymphoma type D was determined to be an other important medical event. Additional information is expected.
This case was reported by a pharmacist via call center representative and described the occurrence of vein disorder in a unk patient who received FLU QUADRIVALENT (split without adjuvant dresden). On an unknown date, the patient received FLU QUADRIVALENT split without adjuvant dresden at an unknown dose. On an unknown date, an unknown time after receiving FLU QUADRIVALENT split without adjuvant dresden, the patient experienced vein disorder and burning sensation. On an unknown date, the outcome of the vein disorder and burning sensation were unknown. It was unknown if the reporter considered the vein disorder and burning sensation to be related to FLU QUADRIVALENT split without adjuvant dresden. A director of pharmacy reported side effects for a patient. The pharmacist told him that a patient received quadrivalent flu vaccine, manufacturer unknown. The pharmacist reported two side effects: pooling and burning. She did not qualify those events to the field rep, so he does not know exactly what she meant by those events.
Patient had intussusception diagnosed by KUB in hospital on 4/27/12. He was sent to hospital for treatment. Unaware of outcome at this time.
Taste problems.  Everything tastes bitter and off.  12 days later still having the bitterness.; This is a spontaneous report from a contactable consumer (patient). A 72-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL3247), via intramuscular route of administration in left arm on 29Jan2021 at 18:45 as single dose for covid-19 immunisation. Medical history included hernia, asthma and reflex. Prior to the vaccination, the patient didn't have COVID-19. Since the vaccination, the patient had been tested for COVID-19 with sars-cov-2 test and resulted negative on 07Feb2021. The patient has known allergies with metoprolol, sulpha, Macrodantin, lisinopril, levaquin, penicillin and latex. Concomitant medication included breo (BREO ELLIPTA), levothyroxine (LEVOTHYROXINE SODIUM), pantoprazole (PANTOPRAZOLE), olmesartan (OLMESARTAN), simvastatin (SIM) taken for an unspecified indication. The patient did not receive any vaccinations within 4 weeks prior to COVID-19 vaccine. On an unspecified date the patient experienced taste problems. Everything tastes bitter and off. 12 days later still having the bitterness. The patient visited emergency room due to event. The patient did not receive any treatment for the events. Outcome of the event was not recovered.
devel mesles like rash, fever 5OCT92; poss infectious mononucleosis;
failed to received the 2nd dose on Moderna COVID-19 vaccine within recommended interval; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (failed to received the 2nd dose on Moderna COVID-19 vaccine within recommended interval) in a 65-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (failed to received the 2nd dose on Moderna COVID-19 vaccine within recommended interval). At the time of the report, PRODUCT DOSE OMISSION ISSUE (failed to received the 2nd dose on Moderna COVID-19 vaccine within recommended interval) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided . No treatment medications were provided..   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Follow-up received on 22-jun-2021 contains no newinformation.
The vaccination was given on 10/17/17 and reported to the pharmacy on the morning of 10/18/17.   The patient said that her left arm was sore, swollen, would not move, and that she had a fever. The patient was told to contact her doctor, and to go to the emergency room for treatment. The pharmacy contacted her doctor directly to make sure they followed up with her. She was told to take benadryl by her doctor, and if no improvement to go to the emergency dept. The patient reported later that day that it had improved somewhat, and that she was not going to the ED or her doctor.
Asthma Attack; profound difficulty in breathing; Asthma is primarily dormant/inactive with daily treatment care of allergy medications.
Patient was administered the Pfizer vaccine a week early (2 weeks after 1st dose). Patient was scheduled for 2nd dose on Thursday 8/12/21, but arrived at the pharmacy on Thursday 8/5/21. Patient called the pharmacy a few hours after receiving the vaccine to notify us that she mistakenly thought it was 8/12/21 and that she had received the vaccine a week early.  We noted down the error and have been following up with the patient to monitor  any side effects that she is experiencing. Patient has only reported arm soreness and fatigue since receiving the vaccine.
pt recvd vax;hissing/ringing in ears constantly;to MD;ear spec;had MRI, blood work all neg;MD put pt on anti-depressants for insomnia;
Within 24 hours of the first dose, I experienced heavy vaginal bleeding, including the passing of large blood clots. Bleeding lasted 28 days. Still heavily bleeding, but no longer passing clots, I received the second dose of the vaccine and clotting began again in earnest.  Now considered hemorrhage bleeding, I became anemic to the point of needing iron and vitamin C supplements, ultrasound testing and weekly blood work as prescribed by my doctor. The bleeding lasted an additional 29 days for a total of 57 days from the first dose of the Moderna Covid-19 vaccine. Additionally, my regular menstrual cycle began again only 18 days later and while lasting longer (21 days), it was not as heavy and no clots were present.
clammy; threw up; shortness of breath/cannot catch her breath; dizzy/spinning; rapid heart beat/palpitation; dripping sweat; felt close to pass out.; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath/cannot catch her breath), DIZZINESS (dizzy/spinning), PALPITATIONS (rapid heart beat/palpitation), HYPERHIDROSIS (dripping sweat) and FEELING ABNORMAL (felt close to pass out.) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 061E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect products included non-company products INFLUENZA VACCINE (FLU VACCINE VII) for an unknown indication and PNEUMOCOCCAL VACCINE POLYSACCH 23V (PNEUMOVAX) for an unknown indication.    Concurrent medical conditions included Hypertension (High blood pressure since last one year). Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HYDROCHLOROTHIAZIDE) for Hypertension.   On 22-Sep-2021, the patient received dose of INFLUENZA VACCINE (FLU VACCINE VII) (unknown route) at an unspecified dose and dose of PNEUMOCOCCAL VACCINE POLYSACCH 23V (PNEUMOVAX) (unknown route) at an unspecified dose. On 22-Sep-2021 at 5:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Sep-2021 at 10:30 PM, the patient experienced DYSPNOEA (shortness of breath/cannot catch her breath), DIZZINESS (dizzy/spinning), PALPITATIONS (rapid heart beat/palpitation), HYPERHIDROSIS (dripping sweat) and FEELING ABNORMAL (felt close to pass out.). On 23-Sep-2021, the patient experienced COLD SWEAT (clammy) and VOMITING (threw up). At the time of the report, DYSPNOEA (shortness of breath/cannot catch her breath), DIZZINESS (dizzy/spinning), PALPITATIONS (rapid heart beat/palpitation), HYPERHIDROSIS (dripping sweat), FEELING ABNORMAL (felt close to pass out.), COLD SWEAT (clammy) and VOMITING (threw up) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 72/56 (Low) Blood pressure was 72/56.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medication was not provided by the reporter
Swollen arm. Slight, small bruise (about 1 inch) at site of the drug administration. It happened right after the drug was administered. We recommended ice pack and BENADRYL for treatment.
Painful axillary lymphadenopathy on same arm as injection site. Family would like it noted that patient and monozygotic twin sister with same reactions; fraternal triplet brother without any reaction.
Redness, firmness, and swelling up tp 4 inches in diameter at the injection site in top of right thigh.  These symptoms noticed around 6:00 pm.  Extreme behavior change in the form of painful constant crying; baby not soothed by any measures.  This behavior change began at 8:15 pm.
Patient presented to facility with respiratory distress, SOB.  Patient admitted from nursing home. Has left sided Pneumonia.
Sudden onset, severe and disabling pain in right leg. Unable to stand, walk, or use leg. Self treatment with ADVIL, heating pad, analgesic cream. Pain started 3 pm on Monday, 9/10 and on Tuesday, 9/11 , it was only slightly improved. Could not stand on leg. Continued self treatment including sitting on floor and stretching. Preparing to call for emergency transport. Improved gradually and continued self-treatment. On Wednesday 9/13 was able to stand on leg. Thursday 9/14 pain gone. Extreme fatigue 36 hours. Prepared to cancel long awaited trip on 9/18 due to possibility I would not be able to walk. Now, feel ok to travel. Very scary situation. Felt totally obliged to report this event. Never had reaction to vaccines and have traveled to other countries in recent years which required many shots. Also...flu vaccine has never been a problem for me in past years. Do not plan to ever get another one.
sore arm; GAVE AN ADULT PATIENT, PEDIATRIC DOSES FOR / HAVRIX; GAVE AN ADULT PATIENT, PEDIATRIC DOSES FOR / HAVRIX / Engerix B; This case was reported by a other health professional via call center representative and described the occurrence of pain in arm in a 48-year-old female patient who received HBV (Engerix B pediatric) for prophylaxis.   Co-suspect products included HAV (Havrix pediatric) for prophylaxis.   On 24th November 2020, the patient received Engerix B pediatric and Havrix pediatric. On 24th November 2020, unknown after receiving Engerix B pediatric and Havrix pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm, underdose and adult use of a child product were unknown.   It was unknown if the reporter considered the pain in arm to be related to Engerix B pediatric and Havrix pediatric.  Additional details were received as follows: The age at vaccination was not reported.   An adult patient, pediatric doses for both Havrix or Engerix, which led to underdose and adult use of a child product. The patient had sore arm. Medical assistant stating she gave a pediatric dose of the Havrix and the pediatric dose of Engerix B to an adult patient on 24th Nov 20 .  The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020237652:FU1 deleted
Pt c/o dizziness. BP 148/90 HR 84 99% RA. RRT called. Transported pt  to Emergency Department.
FEELING OF LUMP AND TIGHTNESS OF THROAT 1007 PATIENT STATES FEELING OF LUMP IN THROAT AND MILD DISCOMFORT. DENIES SHORTNESS OF BREATH, CHEST DISCOMFORT, OR PAIN 1012 PATE STATES THIS FEELING IS BETTER AND IS DRINKING TEA 1020 PATIENT FEELING NOT GETTING ANY WORSE, DENIES ANY DIFFICULTY BREATHING OR SWALLOWING. 1030 PATIENT IS FEELING BETTER, NO PROBLEMS BREATHING OR SWALLOWING. NO HIVES OBSERVED, PATIENT SKIN IS PINK AND WARM TO TOUCH. AND SHE IS TOLERATING TEA 1042 PATIENT INSTRUCTED TO CALL EMERGENCY MEDICAL SERVICES IF ANY SHORTBESS OF BREATH OR CHEST DISCOMFORT WHILE AT HOME. PATIENT VERBALIZES UNDERSTANDING. PATIENT STATES SHE IS FEELING BETTER AND WITH TAKE HER ALLERGY MEDICATION WHEN SHE GETS HOME. PATIENT DROVE HOME